02xl is your source for accurate and trustworthy information so you can make the best choices for your health and wellness.
PS: Please note that 02xl provides this information for the benefit of the rare disease and overweight community. 02xl is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.
Considered the most aggressive type of brain cancer, glioblastoma grows rapidly, destroying healthy tissue. Globally, approximately 300,000 people are diagnosed each year with glioblastoma.
Glioblastoma is a type of cancer affecting glial cells, which connect nerve cells and support brain function.
“It tends to be a tumor that also tends to grow and invade the brain,” says Dr. Alfredo Quinones-Hinojosa, a neurosurgeon at Mayo Clinic. “Sometimes it can be slow and steady, but it tends to grow very fast.”
Despite significant advances in surgery, chemotherapy, immunotherapy and radiation technology, the prognosis of glioblastoma remains poor.
“The median survival of patients with the best therapies tends to be between 12 and 14 months,” says Dr. Quinones-Hinojosa.
There is no known cure for glioblastoma, but treatments may help slow the progression or help stabilize the quality of life. Research is making strides, giving patients more options and hope.
“Research is crucial to find hope and healing on every corner of our operating room, in every corner of our laboratory, and to connect those two, ultimately, through our patients,” says Dr. Quinones-Hinojosa.
2024 Mayo Clinic News Network. Distributed by Tribune Content Agency, LLC.
Citation:
Treatment and research of glioblastoma (2024, April 30)
retrieved 30 April 2024
from https://medicalxpress.com/news/2024-04-treatment-glioblastoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.